StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on Alto Neuroscience (ANRO)

Wed, 17 Jun 2026 06:50:16 -0400

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $50.00 price target on Alto Neuroscience (NYSE: ANRO).

The analyst commented: "On June 15, Alto Neuroscience announced the June 12 publication in Nature Medicine of the results from the PRIME-PRAXOL trial, an independent, randomized, double-blind, placebo-controlled trial conducted by Lund University, showing that pramipexole significantly improved anhedonia in patients with mood disorders and clinically significant anhedonia (link to publication). The trial (n=85, with 82 patients included in the analysis) met its primary endpoint on the Snaith-Hamilton Pleasure Scale (SHAPS), with a mean treatment difference of −4.04 points vs. placebo at week

Alto Neuroscience cites study showing pramipexole reduces anhedonia

Mon, 15 Jun 2026 08:03:43 -0400

Alto Neuroscience Inc. (NYSE: ANRO) highlighted a Nature Medicine publication showing pramipexole significantly reduced anhedonia in patients with mood disorders compared to placebo in an independent study conducted by Lund University researchers.

The PRIME-PRAXOL trial included adults with elevated anhedonia symptoms diagnosed with major depressive disorder, dysthymia, or bipolar depression. Participants received either flexible-dose pramipexole or placebo added to ongoing treatment for nine weeks, followed by a six-month open-label extension.

The study met its primary endpoint, with pramipexole reducing anhedonia more than placebo on the Snaith-Hamilton Pleasure Scale (mean difference -4.04; p=0.006; Hedges' g=0.62). Significant improvements were also observed on independent measures

Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia

Mon, 15 Jun 2026 08:03:00 -0400

– Independent, peer-reviewed, placebo-controlled trial conducted by Lund University showed pramipexole significantly reduced anhedonia (primary endpoint, Hedges’ g=0.62, p=0.006) –

– Benefit extended to independent anhedonia and apathy measures (DARS, AES-S) and was sustained through six months of open-label treatment –

– Findings reinforce the dopaminergic mechanism underlying ALTO-207; potentially pivotal Phase 2b trial in treatment-resistant depression is ongoing with data expected in 2H 2027 –

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today highlighted the publication in Nature Medicine of PRIME-PRAXOL, an independent, randomized, double-blind, placebo-controlled trial of the

Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia

Mon, 15 Jun 2026 08:03:00 -0400

– Independent, peer-reviewed, placebo-controlled trial conducted by Lund University showed pramipexole significantly reduced anhedonia (primary endpoint, Hedges’ g=0.62, p=0.006) –

– Benefit extended to independent anhedonia and apathy measures (DARS, AES-S) and was sustained through six months of open-label treatment –

– Findings reinforce the dopaminergic mechanism underlying ALTO-207; potentially pivotal Phase 2b trial in treatment-resistant depression is ongoing with data expected in 2H 2027 –

Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia

Mon, 15 Jun 2026 08:03:00 -0400

– Independent, peer-reviewed, placebo-controlled trial conducted by Lund University showed pramipexole significantly reduced anhedonia (primary endpoint, Hedges’ g=0.62, p=0.006) –

– Benefit extended to independent anhedonia and apathy measures (DARS, AES-S) and was sustained through six months of open-label treatment –

– Findings reinforce the dopaminergic mechanism underlying ALTO-207; potentially pivotal Phase 2b trial in treatment-resistant depression is ongoing with data expected in 2H 2027 –

Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia

Mon, 15 Jun 2026 08:03:00 -0400

– Independent, peer-reviewed, placebo-controlled trial conducted by Lund University showed pramipexole significantly reduced anhedonia (primary endpoint, Hedges’ g=0.62, p=0.006) –

– Benefit extended to independent anhedonia and apathy measures (DARS, AES-S) and was sustained through six months of open-label treatment –

– Findings reinforce the dopaminergic mechanism underlying ALTO-207; potentially pivotal Phase 2b trial in treatment-resistant depression is ongoing with data expected in 2H 2027 –

Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia

Mon, 15 Jun 2026 08:03:00 -0400

– Independent, peer-reviewed, placebo-controlled trial conducted by Lund University showed pramipexole significantly reduced anhedonia (primary endpoint, Hedges’ g=0.62, p=0.006) –

– Benefit extended to independent anhedonia and apathy measures (DARS, AES-S) and was sustained through six months of open-label treatment –

– Findings reinforce the dopaminergic mechanism underlying ALTO-207; potentially pivotal Phase 2b trial in treatment-resistant depression is ongoing with data expected in 2H 2027 –

Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia

Mon, 15 Jun 2026 08:03:00 -0400

– Independent, peer-reviewed, placebo-controlled trial conducted by Lund University showed pramipexole significantly reduced anhedonia (primary endpoint, Hedges’ g=0.62, p=0.006) –

– Benefit extended to independent anhedonia and apathy measures (DARS, AES-S) and was sustained through six months of open-label treatment –

– Findings reinforce the dopaminergic mechanism underlying ALTO-207; potentially pivotal Phase 2b trial in treatment-resistant depression is ongoing with data expected in 2H 2027 –

Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia

Mon, 15 Jun 2026 08:03:00 -0400

– Independent, peer-reviewed, placebo-controlled trial conducted by Lund University showed pramipexole significantly reduced anhedonia (primary endpoint, Hedges’ g=0.62, p=0.006) –

– Benefit extended to independent anhedonia and apathy measures (DARS, AES-S) and was sustained through six months of open-label treatment –

– Findings reinforce the dopaminergic mechanism underlying ALTO-207; potentially pivotal Phase 2b trial in treatment-resistant depression is ongoing with data expected in 2H 2027 –

Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia

Mon, 15 Jun 2026 08:03:00 -0400

– Independent, peer-reviewed, placebo-controlled trial conducted by Lund University showed pramipexole significantly reduced anhedonia (primary endpoint, Hedges’ g=0.62, p=0.006) –

– Benefit extended to independent anhedonia and apathy measures (DARS, AES-S) and was sustained through six months of open-label treatment –

– Findings reinforce the dopaminergic mechanism underlying ALTO-207; potentially pivotal Phase 2b trial in treatment-resistant depression is ongoing with data expected in 2H 2027 –

Form 4 Alto Neuroscience, Inc. For: May 27 Filed by: Miller Andrew Craig

Fri, 29 May 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260529/26575409.html

Form 4 Alto Neuroscience, Inc. For: May 27 Filed by: Miller Andrew Craig

Fri, 29 May 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260529/26575409.html

Form 3 Alto Neuroscience, Inc. For: May 27 Filed by: Miller Andrew Craig

Fri, 29 May 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260529/26575360.html

Form 3 Alto Neuroscience, Inc. For: May 27 Filed by: Miller Andrew Craig

Fri, 29 May 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260529/26575360.html

Form 8-K Alto Neuroscience, Inc. For: May 27

Thu, 28 May 2026 08:18:00 -0400

si-local-file:///var/storage/secattach/20260528/26561616.html

Form 8-K Alto Neuroscience, Inc. For: May 27

Thu, 28 May 2026 08:18:00 -0400

si-local-file:///var/storage/secattach/20260528/26561616.html

Alto Neuroscience adds Karuna founder Miller to board

Thu, 28 May 2026 08:03:14 -0400